216
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Submit your manuscript to the new open access journal Drug Repurposing. Open for research articles, reviews, discussions, case studies, negative results across the whole spectrum of drug repurposing.

      No article processing charges.

      scite_
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      International Drug Repurposing Patent Landscaping, Part 1: Rare Diseases 2010–2023

      Published
      review-article
        1 ,
      Drug Repurposing
      ScienceOpen
      drug repurposing, patenting, rare diseases
      Bookmark

            Abstract

            In this first installment of a series of papers on landscaping of drug repurposing patents, we present an analysis in the context of rare diseases. Using the RepoScope drug repurposing database, developed as part of the REPO4EU Horizon Europe project, we identified 190 documents that were published through the international PCT (Patent Cooperation Treaty) patent system from 2010 to 2023. These documents claimed utility in a total of 98 rare diseases. We provide detailed tabulated summaries for two representative disease classes: lysosomal storage diseases and muscular dystrophies. High variability in active pharmaceutical ingredients indicated high levels of innovation. Seventy-five percent of rare disease drug repurposing patents were filed by small/medium pharmaceutical companies or universities, often university spin-offs. Big pharmaceutical companies show limited interest in this area, as reflected by their low representation. Approximately one-third of all patent disclosures came from the United States and the European Union (EU). The EU demonstrated a stronger position in patenting for rare diseases than general pharmaceutical patenting. Patentees from China, Korea, and Japan, who are notable in the general pharmaceutical field, showed limited interest in rare disease drug repurposing patents, in contrast to their publication record in this area.

            Main article text

            PROLOGUE TO THE SERIES

            This manuscript is the first in a series that will feature international patent disclosures that claim drug repurposing for a range of diseases with common characteristics. The common feature in the present case is the formal categorization of the new target condition as a rare disease. Before featuring these documents, we shall first explain why this series focuses on patent documents instead of peer-reviewed papers, for which there are numerous reviews available for every field we will discuss.

            Landscaping a specific area of the intellectual property (IP) space for scientific purposes, rather than for patentability or freedom to operate, requires a different set of background knowledge and search techniques compared to reviewing the same scientific field through peer-reviewed publications.

            The purpose of submitting a manuscript to a peer-reviewed journal is to communicate a team’s latest research results and showcase them in the context of other groups’ work. In contrast, filing a patent application marks the beginning of a multi-year process that incurs substantial costs. This process is undertaken only if the applicant, usually not the inventor(s) but their university’s technology transfer office or company, believes that the invention’s potential could be exploited before patent protection expires 20 years after the first filing, also known as the priority date. While getting a patent granted is necessary, it is not sufficient to exploit the invention; however, it does suffice to prevent third parties from exploiting it. Some patent applications are filed solely for the purpose of exclusion, as part of a “patent wall” intended to strategically protect a larger estate. IP can also be used as a bargaining chip in negotiations, even if no actual patent has been granted yet. Therefore, what is disclosed in patent applications is often different from what is presented in manuscripts intended for peer review.

            Although patent documents are available online for free, they are not as easily searchable as scientific journal contributions. Patent codes are used to index them, but these are organized around IP legalities rather than scientific content. While free text searches are possible, the characteristics of patent texts mean that a Boolean search will return many hits that must then be examined by experts to identify the relevant ones. It is important to note that there is no patent code for documents with drug repurposing content.

            What is a PCT Patent Disclosure?

            This series of IP landscapes relies on drug repurposing patent applications published by the Patent Cooperation Treaty (PCT) and represented in RepoScope, a knowledge base currently under development as part of the Horizon Europe project REPO4EU. The project will ultimately launch the Drug Repurposing Platform, a comprehensive open-access online service.

            A PCT document is not yet a patent, but rather an international publication of a patent application. This application is typically filed first at a national or regional patent office and can be “internationalized” within 12 months of its original filing (the priority date). The international application is made public as a document, identified by a code in the format WO/[year of publication]/[serial number], as soon as 18 months have passed since the priority date.

            PCT applications are considered the center of global patenting since almost every life science patent application follows this route to ultimately become an enforceable national and regional patent. It is important to note that, while the descriptive part of the invention will not change during the patenting process, not all claims made on this basis will survive. What claims are ultimately granted is decided by the patent offices, and very often what is granted is considerably narrower in scope than the original attempt.

            INTRODUCTION TO RARE DISEASES

            The current version of the World Health Organization’s (WHO) International Classification of Diseases (ICD-11) includes some 5500 rare diseases and their synonyms, although the actual number is probably close to 8000, and new ones are described constantly. At least 80% of these diseases have a genetic basis, and the majority of these affect children, lack a cure, and are ultimately fatal.

            The WHO defines a rare disease as “a medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons living in any World Health Organisation-defined region of the world.” The European Union (EU) definition keeps the 1 in 2000 prevalence but excludes diseases that are not also life-threatening, chronically debilitating, or inadequately treated. The United States employs a slightly different definition based on the 1983 Orphan Drug Act (amended by the 2002 Rare Diseases Act which established the Office of Rare Diseases at the National Institutes of Health), which requires less than 200,000 individuals in the United States to be affected; based on the 2020 census, this amounts to a prevalence of 1 in 1657.Our discussion will use the WHO definition of rare diseases.

            Rare diseases would mostly not provide sufficient economic incentive for pharmaceutical companies to develop and market drug treatments. Unless premium prices can be charged (which is more difficult for repurposed agents than for new chemical entities), a prevalence of >10–30,000 patients in Europe or the United States is deemed viable from a business perspective by most companies. Governments in all major pharmaceutical markets have implemented initiatives to make such developments attractive by offering reduced regulatory fees, regulatory market exclusivity in addition to any exclusivity based on patents, and tax credits. 1 There are additional incentives with a broader scope, only two of which shall be mentioned here. The European Expert Group on Orphan Drug Incentives was formed in 2020 to develop policy proposals to facilitate EU policy makers to meet rare disease challenges. 2 The US Food and Drug Administration (FDA) has established and funded the Rare Disease Cures Accelerator-Data Analytics Platform to collect and share disease prevalence, patient selection, disease progression, and any data projecting likelihood of patient response to therapy including any genetic data. 3 Such efforts have been met with success, as shown by regulatory submissions, which can use abbreviated paths such as the §505(b)(2) path provided by the FDA, and also by patenting.

            Landscaping the rare disease patent space presents some specific problems. Most rare diseases are known by synonyms, often by several ones. Moreover, several subtypes have been described for the majority of genetically defined rare diseases. This has caused development of specialized ontologies, such as the Orphanet Rare Disease Ontology. However, the much more general Medical Subject Headings (MeSH), according to which the PubMed peer review literature is indexed, and the Disease Ontology (which semantically integrates and extensively cross-maps its terms to the MeSH, ICD, NCI thesaurus, systematized nomenclature of human and veterinary medicine, and online mendelian inheritance in man ontologies) also serve well to give rare diseases unique identifiers. The present discussion is based on Disease Ontology identifiers.

            METHODS

            The RepoScope knowledge base is centered around PCT patent applications with drug repurposing content. It handles its entries in three main modules: conditions, compounds, and targets. Each condition, compound, or molecular target is a named entity that can be linked to other named entities in the same module, and also in any other module. Entries can be made in any module on which the patent document is centered (and thus seems to fit best), without compromising the linkage. Tags can be assigned to any named entity to create meaningful groupings. RepoScope does not differentiate between repurposing of an active pharmaceutical ingredient and drug repositioning (i.e., repurposing of clinical stage drug candidates or approved drugs to indications other than originally targeted), as both types of new uses will appear in PCT documents in the same way.

            In our present work, we analyze the medical conditions with the #raredisease tag. This tag is applied only to documents addressing primary symptoms of at least one rare disease (e.g., chorea in Huntington’s disease); documents related to treatment of secondary symptoms (e.g., seizures in fragile X syndrome) are not included.

            RESULTS

            The RepoScope 2010–2023 data dump contains 190 unique repurposing-related PCT patent documents claiming utility in a total of 98 unique rare diseases (subtypes included under the umbrella term).

            Time Course

            The number of drug repurposing patent applications for rare diseases published through the international PCT system remained low between 2010 and 2016, with only about 5–10 such documents appearing per year. Activity started to take off in 2017 and has reached an average of 20 documents per year for 2020–2023. (Note that this reflects original priority filings made about 18 months earlier.) There was no drop in activity during the Covid-19 pandemic.

            Statistics by Applicants

            Looking at the size and type of applicants, 41% of applications were filed by small and medium corporate entities while 34% came from universities. Hospitals of any type contributed 5%. A remarkable 10% came directly from national authorities and institutions, such as the US Department of Health and Human Services or the French Institut National de la Santé et de la Recherche Médicale. These agencies have large budgets that put few if any limitations on their patenting activities. However, large pharmaceutical companies played a marginal role, filing no more than 3% of drug repurposing patent applications for rare diseases. The remaining 7% were filed by individual inventors whose affiliation at the time of filing could not be immediately determined.

            By nationality, 33% of applicants were based in the United States. The EU (excluding the United Kingdom) contributed about the same share, 35%. Among the EU member states, France was the clear leader, with Spain a distant second. The United Kingdom had a relatively strong position on its own, to a good part because of the rare disease repurposing company, Healx. At 17%, Asian applicants (almost evenly distributed between China, Korea, and Japan) were comparatively underrepresented in terms of PCT disclosure numbers.

            Snapshots of Patent Documents for Selected Rare Disease Groups

            Tables 1 and 2 present the complete lists of drug repurposing patent applications for two important classes of rare diseases: lysosomal storage disease (14 documents) and muscular dystrophies (19 documents).

            Table 1:

            PCT Patent Disclosures Claiming Repurposing for Lysosomal Storage Diseases, 2010–2023.

            Patent CodeCompound(s)Approved Use(s)Claimed New UsesAssignee
            WO/2022/159086GemfibrozilDyslipidemiaKrabbe diseaseRush University Medical Center (US)
            WO/2021/116487Amrinone, nicainoprol, piboserodVariousNiemann–Pick disease type C1SOM Biotech (ES)
            WO/2020/168294AmbroxolMucus liquefactionMucopolysaccharidosis type IIILysosomal and Rare Disorders Research and Treatment Center (US)
            WO/2018/183940SobetiromeDiscontinued dyslipidemia and obesity candidateNiemann–Pick diseaseNeurovia (US)
            WO/2016/038616Memantine, ifenprodilAlzheimer disease, cerebral vasodilationNeuropathic Gaucher diseaseYeda R&D (IL)
            WO/2015/188037AtalurenDuchenne muscular dystrophyMucopolysaccharidosis type IPTC Therapeutics (US)
            WO/2015/011284Repaglinide, pranlukast, zafirlukast, benzbromaroneVariousFabry disease, Gaucher diseaseFondazione Telethon (IT)
            WO/2015/097088BicalutamideProstate cancerLysosomal storage diseasesBCN Peptides (ES)
            WO/2015/049471OdiparcilDiscontinued antithrombotic candidateMucopolysaccharidosis type VIInventiva Pharma (FR)
            WO/2014/143992Chlorotrianisene, clofoctol, tulobuterolVariousKrabbe disease, Gaucher disease, metachromatic leukodystrophyRochester University (US)
            WO/2014/022841CyclodextrinsInclusion agents in >30 drugsNiemann–Pick disease type C1DHHS (US)
            WO/2013/016315AvasimibeDiscontinued dyslipidemia candidateNiemann–Pick diseaseDartmouth College (US)
            WO/2012/094600Dihydropyridine Ca channel blockersHypertonia, heart diseaseGaucher disease, etc.William Marsh Rice University (US)
            WO/2011/109448Antiandrogens (flutamide, spironolactone, etc.)Prostate cancer, hypertoniaFabry diseaseBaylor Research Institute (US)

            DHHS, US Department of Health and Human Services; PCT, Patent Cooperation Treaty.

            Table 2:

            PCT Patent Disclosures Claiming Repurposing for Muscular Dystrophies, 2010–2023.

            Patent CodeCompound(s)Approved Use(s)Claimed New UsesAssignee
            WO/2023/244738PioglitazoneType 2 diabetesDuchenne muscular dystrophyJohns Hopkins University (US)
            WO/2023/175010BazedoxifeneOsteoporosisLimb girdle muscular dystrophyGenethon, Inserm, etc. (FR)
            WO/2023/073134BosentanPulmonary arterial hypertensionDuchenne muscular dystrophy, facioscapulohumeral dystrophyAssociation Institut de Myologie, Inserm
            WO/2022/231257OxiracetamNootropicDuchenne muscular dystrophyKSB Tugen (KR)
            WO/2021/059270Mefenamic acid and related fenamate NSAIDsInflammatory painVarious muscular dystrophiesYissum R&D (IL)
            WO/2019/084499Rebastinib, sorafenib, imatinibChronic myeloid leukemiaFacioscapulohumeral dystrophyGenea Biocells (US)
            WO/2018/177893NintedanibIdiopathic pulmonary fibrosisDuchenne muscular dystrophyBoehringer Ingelheim (DE)
            WO/2017/013031Fluoxetine, vortioxetineDepression, anxietyDuchenne muscular dystrophyInstitut Pasteur, etc. (FR)
            WO/2017/009644Sunitinib, vandetanibSolid tumorsFacioscapulohumeral dystrophyKing’s College London (UK)
            WO/2016/190697ExenatideType 2 diabetesDuchenne muscular dystrophyImmunoforge (KR)
            WO/2015/189534 WO/2014/199171BenserazideParkinson’s diseaseDuchenne muscular dystrophyProximagen (US)
            WO/2015/050581TadalafilErectile dysfunction, pulmonary arterial hypertensionBecker muscular dystrophy, Duchenne muscular dystrophyCedars-Sinai Medical Center (US)
            WO/2015/022386Metformin, tetrahydrobiopterin with L-arginine or L-citrullineType 2 diabetesBecker muscular dystrophy, Duchenne muscular dystrophyUniversitäts-Kinderspital beider Basel (CH)
            WO/2014/190250AtaciguatDiscontinued candidate for peripheral artery disease and neuropathic painDuchenne muscular dystrophyJohns Hopkins University, etc. (US)
            WO/2014/1809965-AzacytidineLeukemias and myelodysplastic syndromesDuchenne muscular dystrophyUniversität Heidelberg (DE)
            WO/2012/067262G-CSFNeutropenia, stem cell transplantationDuchenne muscular dystrophyIndividuals (JP)
            WO/2012/016930AmlexanoxAphthous ulcers, inflammationDuchenne muscular dystrophyUniversité de Lille, etc. (FR)
            WO/2010/010127SiponimodMultiple sclerosisVarious muscular dystrophies and inclusion body myositisNovartis (CH)

            NSAID, nonsteroidal anti-inflammatory drug; PCT, Patent Cooperation Treaty.

            DISCUSSION

            Tables 1 and 2 demonstrate the wide range of approved uses for drug repurposing patent applications in two representative rare disease categories: lysosomal storage diseases and muscular dystrophies. Lysosomal storage diseases are inherited metabolic disorders resulting from defects in lysosomal function or intracellular transport. Muscular dystrophies are caused by loss-of-function mutations in genes coding for essential muscle proteins, such as dystrophin. The original indication’s broadness reflects the diversity of well-established mechanisms and molecular targets. Only one case, ataluren, which is approved for the therapy of Duchenne muscular dystrophy and was claimed for mucopolysaccharidosis type I by its originator, has been approved for another rare disease.

            The examples presented varying extents of data, and the evidence level also varied, as is typical with pharmaceutical patents. This is a natural consequence of the fact that patents are often filed in the early stages of development, especially in highly competitive settings. Applicants typically disclose only the required minimum and may have additional and/or more relevant data available at the priority date, which they could use during the examination process.

            Seventy-five percent of all rare disease drug repurposing patents were filed by small and medium pharmaceutical companies or universities. Distinguishing between the two can be difficult, as small pharmaceutical companies often originate as university spin-offs founded to exploit inventions made by academic inventors at their universities. The limited interest of big pharmaceutical companies in drug repurposing, particularly in small markets, is reflected by their low representation. It is worth noting that national research institutions accounted for at least 10% of all applications. Additionally, it is possible that some of the 5% of applications filed by hospitals and their organizations were from public institutions, which were not distinguished from private hospitals and those attached to public universities in our count.

            During the observation period from 2010 to 2023, approximately one-third of all rare disease drug repurposing patent applications published through the PCT system were contributed by both the United States and the EU. The dataset shows that the EU has a stronger position in patenting drug repurposing discoveries for rare diseases compared to general pharmaceutical patent applications. This observation is consistent with the period of 2011–2014. 4 In contrast, patentees from China, Korea, and Japan, who are respectable in the general pharmaceutical field, appear to have limited interest in patenting their drug repurposing discoveries for rare diseases. This is not in line with their much larger fraction of peer-reviewed manuscripts in this field. The question why Asian researchers translate a smaller fraction of their repurposing innovations to the international patent space would warrant closer investigation.

            Our present study has limitations that are essentially those of the RepoScope database. Its entries are identified and validated through manual screening of the PCT database by a drug repurposing expert. As a result, its specificity for actual drug repurposing is close to 100%, but some documents with such content might have been missed if their title, abstract, and claim section are not suggestive of drug repurposing.

            In summary, we find that most of the drug repurposing innovations in the rare disease field that result in international PCT patent disclosures are filed by small and medium corporations and universities, a significant part of which are situated in Europe or the United States. A highly diverse range of approved (or in some cases, discontinued) active pharmaceutical ingredients has been claimed for two representative rare disease classes: lysosomal storage disorders and muscular dystrophies.

            CONFLICTS OF INTEREST

            The author declares no conflict of interest.

            DATA AND CODE AVAILABILITY

            Data and code availability does not apply.

            REFERENCES

            1. Epps C, Bax R, Croker A, et al.. Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Ther Innov Regul Sci. 2022. Vol. 56(6):964–975. [Cross Ref]

            2. Aartsma-Rus A, Dooms M, Le Cam Y. Orphan medicine incentives: How to address the unmet needs of rare disease patients by optimizing the European orphan medicinal product landscape guiding principles and policy proposals by the European Expert Group for orphan drug incentives (OD Expert Group). Front Pharmacol. 2021. Vol. 12:744532. [Cross Ref]

            3. Barrett JS, Betourne A, Walls RL, et al.. The future of rare disease drug development: The rare disease cures accelerator data analytics platform (RDCA-DAP). J Pharmacokinet Pharmacodyn. 2023. Vol. 50(6):507–519. [Cross Ref]

            4. Mucke HAM, Mucke E. Sources and targets for drug repurposing: Landscaping transitions in therapeutic space. Assay Drug Dev Technol. 2015. Vol. 13(6):319–324. [Cross Ref]

            Author and article information

            Journal
            dr
            Drug Repurposing
            ScienceOpen (Berlin )
            2941-2528
            3 July 2024
            : 1
            : 1
            : e20240012
            Affiliations
            [1 ] H.M. Pharma Consultancy, A-1160 Vienna, Austria;
            Author notes
            Author information
            https://orcid.org/0000-0002-1491-6250
            Article
            10.58647/DRUGREPO.24.1.0012
            7462c977-f2ba-4f41-b73f-bbd46e1e857a
            2024 The Author(s).

            This work has been published open access under Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.

            History
            : 02 April 2024
            : 13 June 2024
            Page count
            Tables: 2, References: 4, Pages: 5
            Funding
            Funded by: funder-id http://dx.doi.org/10.13039/100018696, HORIZON EUROPE Health;
            Award ID: 101057619

            drug repurposing,patenting,rare diseases

            Comments

            Comment on this article